Member Info for gadgie

As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in ABCAM, we have a world-leading partner capable of maximising the commercial potential of the Affimer® reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus.

USA apologies

Question is Abcam use already selling via its on-line catalogue ?

https://www.abcam.com/products?keywords=COVID%2019%20Spike%20Protein&selected.classification=ELISA+and+Matched+Antibody+Pair+Kits

https://www.news-medical.net/news/20210630/Scientists-uncover-new-way-to-target-a-mutant-protein-that-causes-the-deadliest-of-cancers.aspx

The study was funded by the Wellcome Trust, the Medical Research Council, the Technology Strategy Board and Avacta and is published today (30 June 2021)

Medusa 19 are one of multiple selected suppliers to the NHS Microbiology Framework Lot 1 for Goods and Services for the supply of SARS-CoV-2 Lateral Flow Tests throughout the UK. The Framework Contract which will run for the next 4 years and has a value of up to £3 Billion.
This Framework Contract allows the provision to all UK Government Departments and Trusts across England, Scotland, Northern Ireland and Wales subject to access agreement signature and Schedule 6 pricing, to supply the Rapid Saliva Protein Test (RSPT) and Avacta’s professional-use AffiDx SARS-CoV- 2 Antigen Lateral Flow Tests.
The Medusa tests detailed above and other parties lateral flow tests are now available for purchase by various government departments subject to their demand requirements.
https://avacta.com/wp-content/uploads/2021/09/M19-framework-text.pdf

https://www.nature.com/articles/d43747-021-00107-w

Ample news flow is expected over 18-24 months, providing multiple value-inflection points. Our valuation is £710m, equivalent to 280p/share.
https://www.trinitydelta.org/research-notes/so-much-more-than-a-play-on-covid-testing/

Up to $180 million in upfront, near term payments and development milestones

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed an Affimer® therapeutics development partnership and license agreement with LG Chem Life Sciences (LG Chem), part of the South Korean LG Group, to develop Affimer® therapeutics in several disease areas.

This multi-target therapeutics development agreement provides for upfront and near-term milestone payments, plus longer-
From 2018 --- what was this weeks undisclosed Sum ?
https://www.ipgroupplc.com/media/portfolio-news/2018/2018-12-10

term clinical development milestones totalling $180 million. Avacta will also receive royalties on any future product sales and LG Chem will cover Avacta's costs of research and development associated with the collaboration. Avacta may receive an additional $130 million in option fees and milestone payments should LG elect to exercise their options for additional targets.

Apologies ...is this our test that Medusa is selling

Medusa's initial focus will be on Covid-19 home testing. ... and unique saliva-based Covid-19 rapid test being developed by Avacta based on
https://www.medusa19.com/en/rapid-saliva-protein-test/

This switchover is part of Ofgem's Supplier of Last Resort (SOLR) process. In line with the regulatory framework for the SOLR process, it has been agreed that all costs incurred by British Gas that it is not able to recover as a result of taking on the customers, including additional costs of buying energy, the refund of credit balances, and other operating costs, will be recoverable through the established industry levy in a timely manner. British Gas will do everything it can to minimise those costs.

All costs covered and possibly million plus more customers ...what's not to like

At the start of 2021 there were 70 energy suppliers in the UK but it is feared as few as 10 could be left by the end of the year. A senior executive at one of the UK’s largest energy companies said the estimate that 10 would survive is “optimistic”, the BBC reported.

Yesterday was a classic example how this share is traded see how many times a largish rise has been wiped out PM .... MMs are having a field day no doubt same will happen Monday drop followed by rise followed by sell off PM

Sainsbury’s is undeniably a good target for private equity with a considerable store estate, with the company having more than $10bn in property assets – more than its current market cap by decent margin.

https://www.thisismoney.co.uk/money/markets/article-9918341/Sainsburys-shares-jump-11-takeover-bid-speculation.html

Over 10 Billion in assets is this correct

https://www.fool.com/earnings/call-transcripts/2021/08/19/tremor-international-ltd-trmr-q2-2021-earnings-cal/

Just out, Finncap upgrade to 1400p target. Wow

Outstanding results ...
the Company intends to use the net proceeds from this offering for working capital, general corporate purposes and to fund incremental growth, including possible acquisitions in the future

o Cash and cash equivalents of $275.5 million and zero debt as of June 30, 2021

Morning all ...Lloyds sitting on 4/5 Billion Excess Money luvely jubbly ....Let's see a good start

22 Billion spent on PPI and that is now History ...... Imagine what Lloyds can do moving forward with a starting point of 4+ Billion ...

Mon not Bad what will Tues Bring , will we see a rush before Ex Divi ?